Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation

Yantao Zhang1, Yanqin Ji2,3, Yanyang Tu3,4,5

  • 1Department of Clinical Medicine, The Fifth Clinical Institute, Zunyi Medical University, Zhuhai, Guangdong, China.

Frontiers in Immunology
|October 16, 2025
PubMed

Insights

Autophagy, a cellular recycling process, promotes resistance to doxorubicin (DOX) chemotherapy by helping cancer cells survive. Targeting autophagy could enhance DOX effectiveness and reduce cancer treatment toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Doxorubicin (DOX) is a key chemotherapy agent, but its efficacy is limited by acquired drug resistance.
  • Autophagy, a cellular degradation process, plays a dual role in cancer, often promoting survival and chemoresistance.

Purpose of the Study:

  • To review the intricate relationship between autophagy and DOX resistance.
  • To elucidate the molecular mechanisms underlying autophagy's role in DOX resistance.
  • To explore therapeutic strategies targeting autophagy to overcome DOX resistance.

Main Methods:

  • Literature review of pre-clinical and clinical studies.
  • Analysis of molecular pathways involved in autophagy induction by DOX.
  • Examination of genetic, microenvironmental, and non-coding RNA factors influencing autophagy.

Main Results:

  • Autophagy generally acts as a pro-survival mechanism, enhancing chemoresistance by recycling cellular components and inhibiting apoptosis.
  • DOX can induce autophagy via ROS generation, DNA damage response, and the AMPK/mTOR pathway.
  • Context-specific adaptations like mitophagy and lysosomal remodeling contribute to DOX resistance.

Conclusions:

  • Autophagy is a critical determinant of DOX resistance, acting as both a biomarker and a therapeutic target.
  • Modulating autophagy through inhibitors, natural compounds, or combination therapies shows promise for improving DOX sensitivity.
  • Clinical translation requires developing effective autophagy-targeted drugs for combination therapies to enhance cancer treatment outcomes.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.8K